128 related articles for article (PubMed ID: 3622601)
1. Myasthenic sera recognize the human acetylcholine receptor bound to thymopoietin.
Morel E; Vernet-der Garabedian B; Raimond F; Audhya TK; Goldstein G; Bach JF
Eur J Immunol; 1987 Aug; 17(8):1109-13. PubMed ID: 3622601
[TBL] [Abstract][Full Text] [Related]
2. Interactions of the thymic polypeptide hormone thymopoietin with neuronal nicotinic alpha-bungarotoxin binding sites and with muscle-type, but not ganglia-type, nicotinic acetylcholine receptor ligand-gated ion channels.
Lukas RJ; Audhya T; Goldstein G; Lucero L
Mol Pharmacol; 1990 Dec; 38(6):887-94. PubMed ID: 1701215
[TBL] [Abstract][Full Text] [Related]
3. Thymopoietin, a potent antagonist at nicotinic receptors in C2 muscle cell cultures.
Quik M; el-Bizri H; Audhya T; Goldstein G
Mol Pharmacol; 1991 Mar; 39(3):324-31. PubMed ID: 2005877
[TBL] [Abstract][Full Text] [Related]
4. Thymopoietin inhibits function and ligand binding to nicotinic receptors at the neuromuscular junction.
Quik M; Collier B; Audhya T; Goldstein G
J Pharmacol Exp Ther; 1990 Sep; 254(3):1113-9. PubMed ID: 1967127
[TBL] [Abstract][Full Text] [Related]
5. Enzyme-linked immunosorbent assay for antibody against the nicotinic acetylcholine receptor in human myasthenia gravis.
Kawanami S; Tsuji R; Oda K
Ann Neurol; 1984 Feb; 15(2):195-200. PubMed ID: 6367620
[TBL] [Abstract][Full Text] [Related]
6. Expression of the alpha 7 subunit of the nicotinic acetylcholine receptor in normal and myasthenic human thymuses.
Navaneetham D; Penn A; Howard J; Conti-Fine BM
Cell Mol Biol (Noisy-le-grand); 1997 May; 43(3):433-42. PubMed ID: 9193799
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of myasthenic immunoglobulins against the lethal toxicity of alpha bungarotoxin.
Vernet-der Garabedian B; Bach JF; Morel E
Clin Exp Immunol; 1987 Apr; 68(1):130-7. PubMed ID: 3652512
[TBL] [Abstract][Full Text] [Related]
8. Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies.
Graus YF; de Baets MH; Parren PW; Berrih-Aknin S; Wokke J; van Breda Vriesman PJ; Burton DR
J Immunol; 1997 Feb; 158(4):1919-29. PubMed ID: 9029134
[TBL] [Abstract][Full Text] [Related]
9. Human acetylcholine receptor presentation in myasthenia gravis. DR restriction of autoimmune T epitopes and binding of synthetic receptor sequences to DR molecules.
Manfredi AA; Yuen MH; Moiola L; Protti MP; Conti-Tronconi BM
J Immunol; 1994 Apr; 152(8):4165-74. PubMed ID: 7511671
[TBL] [Abstract][Full Text] [Related]
10. Combined effects of a thymic peptide, thymopoietin and myasthenic patient sera in rat myotube culture.
Eymard B; Aimé C; Cottin C; Morel E; Goldstein G; Bach JF; Berrih-Aknin S
J Neurol Sci; 1992 Oct; 112(1-2):216-22. PubMed ID: 1343090
[TBL] [Abstract][Full Text] [Related]
11. Acetylcholine receptor in rabbit thymus: antigenic similarity between acetylcholine receptors of muscle and thymus.
Ueno S; Wada K; Takahashi M; Tarui S
Clin Exp Immunol; 1980 Dec; 42(3):463-9. PubMed ID: 7214741
[TBL] [Abstract][Full Text] [Related]
12. Extracellular domains of the beta, gamma and epsilon subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic autoantibodies: a combination of immunoadsorbents results in increased efficiency.
Kostelidou K; Trakas N; Tzartos SJ
J Neuroimmunol; 2007 Oct; 190(1-2):44-52. PubMed ID: 17764755
[TBL] [Abstract][Full Text] [Related]
13. alpha-Bungarotoxin displacing antibody in myasthenia gravis.
Barkas T; Simpson JA
J Clin Lab Immunol; 1982 Nov; 9(2):113-7. PubMed ID: 7154056
[TBL] [Abstract][Full Text] [Related]
14. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera.
Tzartos SJ; Bitzopoulou K; Gavra I; Kordas G; Jacobson L; Kostelidou K; Lagoumintzis G; Lazos O; Poulas K; Sideris S; Sotiriadis A; Trakas N; Zisimopoulou P
Ann N Y Acad Sci; 2008; 1132():291-9. PubMed ID: 18567880
[TBL] [Abstract][Full Text] [Related]
15. Multiple forms of anti-acetylcholine receptor antibody in myasthenia gravis.
Mittag T; Massa T; Kornfeld P; Papatestas A; Bender A; Genkins G
Muscle Nerve; 1981; 4(1):16-25. PubMed ID: 6164920
[TBL] [Abstract][Full Text] [Related]
16. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis.
Howard FM; Lennon VA; Finley J; Matsumoto J; Elveback LR
Ann N Y Acad Sci; 1987; 505():526-38. PubMed ID: 3479935
[TBL] [Abstract][Full Text] [Related]
17. [Antibodies in myasthenia gravis].
Eymard B
Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
[TBL] [Abstract][Full Text] [Related]
18. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy.
Psaridi-Linardaki L; Trakas N; Mamalaki A; Tzartos SJ
J Neuroimmunol; 2005 Feb; 159(1-2):183-91. PubMed ID: 15652418
[TBL] [Abstract][Full Text] [Related]
19. Antigenic modulation of human myotube acetylcholine receptor by myasthenic sera. Serum titer determines receptor internalization rate.
Tzartos SJ; Sophianos D; Zimmerman K; Starzinski-Powitz A
J Immunol; 1986 May; 136(9):3231-8. PubMed ID: 3958494
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal anti-idiotopic antibodies against myasthenia-inducing anti-acetylcholine receptor monoclonal antibodies. Preponderance of nonparatope-directed antibodies affecting antigen binding.
Agius MA; Geannopoulos CJ; Fairclough RH; Richman DP
J Immunol; 1988 Jan; 140(1):62-8. PubMed ID: 3257231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
